Available dose strengths typically include 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg
Encapsulation of exenatide in poly-(D, L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes
For most people, the real challenge isnt losing weight its keeping it off
Thats why you wont find professional organizations like the American Diabetes Association recommending it
Patients discontinuing GLP-1 medications should monitor for signs of gallbladder problems (severe abdominal pain, especially after meals), pancreatitis (persistent severe abdominal pain, sometimes with vomiting), or significant hyperglycemia